18.02
Schlusskurs vom Vortag:
$18.01
Offen:
$18.28
24-Stunden-Volumen:
197.54K
Relative Volume:
0.78
Marktkapitalisierung:
$817.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.24%
1M Leistung:
+7.29%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Firmenname
Maplight Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare MPLT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
MPLT
Maplight Therapeutics Inc
|
18.02 | 817.17M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-21 | Eingeleitet | Jefferies | Buy |
| 2025-11-21 | Eingeleitet | Leerink Partners | Outperform |
| 2025-11-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-21 | Eingeleitet | Stifel | Buy |
Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Consensus Price Target from Analysts - Defense World
USA Herald - USA Herald
MapLight Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
MapLight Therapeutics Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
MapLight Therapeutics Insider Makes a Major Move With Fresh Stock Sale - TipRanks
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $13,358.40 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $39,575.85 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 11,264 Shares of Stock - MarketBeat
Director Malenka sells 14,195 MapLight (MPLT) shares to cover RSU taxes - Stock Titan
MapLight Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity - Defense World
Insider Buying: George Pavlov Acquires 25,000 Shares of MapLight Therapeutics Inc (MPLT) - GuruFocus
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $177,171.20 in Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $77,694.54 in Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director George Pavlov Purchases 10,658 Shares - MarketBeat
MapLight Therapeutics director Pavlov buys shares worth $441k By Investing.com - Investing.com Canada
Malenka Robert C. sells Maplight Therapeutics (MPLT) shares for $220,632 By Investing.com - Investing.com South Africa
Malenka Robert C. sells Maplight Therapeutics (MPLT) shares for $220,632 - Investing.com
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 12,116 Shares of Stock - MarketBeat
Forbion discloses 7.1% MapLight Therapeutics (MPLT) ownership stake - Stock Titan
Big Insider Shake-Up at MapLight Therapeutics as Directors Make Opposite Moves - TipRanks
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 6,622 Shares of Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Timothy John Garnett Buys 14,124 Shares - MarketBeat
Capital Markets Group Of The Year: Cooley - Law360
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell? - Defense World
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Average Price Target from Brokerages - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownTime to Sell? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Malenka sells MapLight (MPLT) shares worth $126,860 By Investing.com - Investing.com Canada
Malenka sells MapLight (MPLT) shares worth $126,860 - Investing.com
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 7,039 Shares of Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $119,743.32 in Stock - Defense World
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 - Investing.com India
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 By Investing.com - Investing.com Australia
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 6,524 Shares of Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 21,262 Shares - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $119,743.32 in Stock - MarketBeat
MPLT SEC FilingsMapLight Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Maplight Therapeutics (NASDAQ:MPLT) Shares Up 4.8% – Here’s Why - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 4.8%Still a Buy? - MarketBeat
Biopharma financings pick up in Q4 to cap uneven 2025 recovery - BioWorld MedTech
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7.7%Here's Why - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 10.5%Time to Buy? - MarketBeat
Finanzdaten der Maplight Therapeutics Inc-Aktie (MPLT)
Es liegen keine Finanzdaten für Maplight Therapeutics Inc (MPLT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):